(20R)-人参皂苷Rg3 | CAS:38243-03-7

IC50 Value & Target:

In Vitro: Ginsenoside Rg3(R) underwent single direction chiral inversion to 20(S)-Rg3 in rats. Stereoselective pharmacokinetic parameters, me tabolic degrees and chiral inversion extents of Rg3 epimers in rats were also discussed [1]. Ginsenoside Rg3(R), exhibited relatively long tmax values, had different tmax values, which should be due to their differences in the substituted groups, this pharmacokinetic identification of multiple ginsenosides of GTSSL in rat plasma provides a significant basis [2].

In Vivo: The present invention 20 (R)-ginsenosides Rg3 fat protoplast encapsulation rate can reach 90%, and prepn. method is simple and efficient, and the prepd. composite lipid cell toxicity is low, the cycle is long, and the extracorporeal biol. physics characterization studies have good e valuation results, so the 20(R)-ginsenosides Rg3/cation lipoid/cholesterol/folic acid liposome drug is safe and efficient, has strong targeting, and the invention provides a new way for the research and development of anticancer drugs [3].